BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage

Reuters11-25

BUZZ-<a href="https://laohu8.com/S/IRD">Opus Genetics</a> gets 'overweight' rating as Piper Sandler initiates coverage

** Piper Sandler initiates coverage on Opus Genetics IRD.O with an "overweight" rating; sets PT at $7, reflecting about 250% upside on the stock's last close

** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket

** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease (LCA5)

** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster

** All eight brokerages rate the stock "buy" or higher; their median PT is $8 - data compiled by LSEG

** As of last close, IRD stock is up ~68.1%

(Reporting by Anuj T in Bengaluru)

((anuj.t@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586203134?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586203134","market":"us","top_or_hot":-1,"title":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/IRD\">Opus Genetics</a> gets 'overweight' rating as Piper Sandler initiates coverage</title></head><body><p>** Piper Sandler initiates coverage on Opus Genetics <span>IRD.O</span> with an \"overweight\" rating; sets PT at $7, reflecting about 250% upside on the stock's last close</p><p>** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket  </p><p>** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease (LCA5)</p><p>** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster</p><p>** All eight brokerages rate the stock \"buy\" or higher; their median PT is $8 - data compiled by LSEG</p><p>** As of last close, IRD stock is up ~68.1%</p><p> (Reporting by Anuj T in Bengaluru)</p><p> ((anuj.t@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/IRD\">Opus Genetics</a> gets 'overweight' rating as Piper Sandler initiates coverage</title></head><body><p>** Piper Sandler initiates coverage on Opus Genetics <span>IRD.O</span> with an \"overweight\" rating; sets PT at $7, reflecting about 250% upside on the stock's last close</p><p>** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket  </p><p>** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease (LCA5)</p><p>** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster</p><p>** All eight brokerages rate the stock \"buy\" or higher; their median PT is $8 - data compiled by LSEG</p><p>** As of last close, IRD stock is up ~68.1%</p><p> (Reporting by Anuj T in Bengaluru)</p><p> ((anuj.t@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRD","symbol_name":"OPUS GENETICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10OR:1","article_id":"2586203134","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586203134","pubTimestamp":1764072213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage** Piper Sandler initiates coverage on Opus Genetics IRD.O with an \"overweight\" rating; sets PT at $7, reflecting about 250% upside on the stock's last close** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket  ** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease ** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster** All eight brokerages rate the stock \"buy\" or higher; their median PT is $8 - data compiled by LSEG** As of last close, IRD stock is up ~68.1%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRD":"OPUS GENETICS INC","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Piper Sandler开始报道，BUZZ-Opus Genetics获得“增持”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRD":0.9},"content_text":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage** Piper Sandler initiates coverage on Opus Genetics IRD.O with an \"overweight\" rating; sets PT at $7, reflecting about 250% upside on the stock's last close** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket  ** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease (LCA5)** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster** All eight brokerages rate the stock \"buy\" or higher; their median PT is $8 - data compiled by LSEG** As of last close, IRD stock is up ~68.1% (Reporting by Anuj T in Bengaluru) ((anuj.t@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586203134","isCrawlerRequest":true}